Treatment of pediatric pulmonary hypertension

References

• AndrewsRPulmonary hypertension in pediatricsCurr Opin Ped200214603605
   Google Scholar
• GibbsJRecommendations on the management of pulmonary hypertension in clinical practiceHeart200186Suppl 111311410544
   PubMedGoogle Scholar
• TullohRCongenital heart disease in relation to pulmonary hypertension in paediatric practicePaediatr Respir Rev2005617418016153566
   PubMedGoogle Scholar
• FreedMDInvasive diagnostic and therapeutic techniques Part 1: cardiac catheterisationAdamsFHHeart Disease in Infants, Children and AdolescentsLondonWilliams and Wilkins2000130146
   Google Scholar
• AndrewsRAtrial septal defect with failure to thrive in infancy: hidden pulmonary vascular disease?Pediatr Cardiol20022352853012211202
   PubMed Web of Science ®Google Scholar
• SimonneauGClinical classification of pulmonary hypertensionJ Am Coll Cardiol20044312 Suppl S5S12S15194173
   PubMed Web of Science ®Google Scholar
• RabinovichMPathobiology of pulmonary hypertensionAnnu Rev Pathol2007236939918039104
   PubMed Web of Science ®Google Scholar
• RabinovitchMVascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defectsCirculation1984696556676697454
   PubMed Web of Science ®Google Scholar
• PietraGGHistopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension RegistryCirculation198980119812062805258
   PubMed Web of Science ®Google Scholar
• JefferyTKMolecular and cellular basis of pulmonary vascular remodelling in pulmonary hypertensionProg Cardiovasc Dis20024517320212525995
   PubMed Web of Science ®Google Scholar
• RichSPrimary pulmonary hypertension. A national prospective studyAnn Intern Med19871072162233605900
   PubMed Web of Science ®Google Scholar
• WidlitzAPulmonary arterial hypertension in childrenEur Respir J20032115517612570125
   PubMed Web of Science ®Google Scholar
• D’AlonzoGESurvival in patients with primary pulmonary hypertension. Results from a national prospective registryAnn Intern Med19911153433491863023
   PubMed Web of Science ®Google Scholar
• RichSClinical insights into the pathogenesis of primary pulmonary hypertensionChest19981143 Suppl237S241S9741575
   PubMed Web of Science ®Google Scholar
• National Pulmonary Hypertension Centres of the UK and IrelandConsensus statement on the management of pulmonary hypertension in clinical practice in the UK and IrelandThorax200863ii1ii4118308974
   PubMed Web of Science ®Google Scholar
• ManesAPulmonary hypertension: classification and diagnostic algorithmItal Heart J2005683483916270476
   PubMedGoogle Scholar
• MaiyaSResponse to bosentan in children with pulmonary hypertensionHeart20069266467016216850
   PubMed Web of Science ®Google Scholar
• AtzAMCombined effects of nitric oxide and oxygen during acute pulmonary vasodilator testingJ Am Coll Cardiol19993381381910080486
   PubMed Web of Science ®Google Scholar
• MikhailGAn evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertensionEur Heart J1997189149915049458458
   PubMed Web of Science ®Google Scholar
• MuthuranguVNovel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flowCirculation2004110782683415302793
   PubMed Web of Science ®Google Scholar
• MuthuranguVMeasurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterizationAm J Physiol Heart Circ Physiol20052893H1301H130615879483
   PubMed Web of Science ®Google Scholar
• HoeperMMGoal-oriented treatment and combination therapy for pulmonary arterial hypertensionEur Respir J20052685886316264047
   PubMed Web of Science ®Google Scholar
• LanglebenDEndothelin-1 in acute lung injury and the adult respiratory distress syndromeAm Rev Respir Dis1993148(6 Pt 1):164616508256914
   PubMed Web of Science ®Google Scholar
• DavieNET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cellsAm J Respir Crit Care Med2002165339840511818328
   PubMed Web of Science ®Google Scholar
• HervéPIncreased plasma serotonin in primary pulmonary hypertensionAm J Med19959932492547653484
   PubMed Web of Science ®Google Scholar
• ChristmanBWAn imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertensionN Engl J Med1992327270751603138
   PubMed Web of Science ®Google Scholar
• PetkovVVasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertensionJ Clin Invest200311191339134612727925
   PubMed Web of Science ®Google Scholar
• BandoKPulmonary hypertension after operations for congenital heart disease: analysis of risk factors and managementJ Thorac Cardiovasc Surg1996112616001607discussion 160716098975852
   PubMed Web of Science ®Google Scholar
• LindbergLHow common is severe pulmonary hypertension after pediatric cardiac surgery?J Thorac Cardiovasc Surg200212361155116312063463
   PubMed Web of Science ®Google Scholar
• OhsumiHEffects of fentanyl on carotid sinus baroreflex control of circulation in rabbitsAm J Physiol1989256(3 Pt 2):R625R6312493749
   PubMedGoogle Scholar
• AdriaenssensTAdvanced therapy may delay the need for transplantation in patients with the Eisenmenger syndromeEur Heart J200627121472147716707548
   PubMed Web of Science ®Google Scholar
• BadeschDBMedical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelinesChest200713161917192817565025
   PubMed Web of Science ®Google Scholar
• GalièNGuidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of CardiologyEur Heart J200425242243227815589643
   PubMed Web of Science ®Google Scholar
• TaylorCJRisk of cardiac catheterization under anaesthesia in children with pulmonary hypertensionBr J Anaesth200798565766117401143
   PubMed Web of Science ®Google Scholar
• SandovalJNocturnal oxygen therapy in patients with the Eisenmenger syndromeAm J Respir Crit Care Med200116491682168711719310
   PubMed Web of Science ®Google Scholar
• SteudelWInhaled nitric oxide: basic biology and clinical applicationsAnesthesiology19999141090112110519513
   PubMed Web of Science ®Google Scholar
• AdatiaIEffect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shuntBr Heart J19947254524567818962
   PubMedGoogle Scholar
• BeghettiMContinuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patientsBr Heart J199573165687888265
   PubMedGoogle Scholar
• DavidsonDInhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study GroupPediatrics1998101(3 Pt 1):3253349480993
   PubMed Web of Science ®Google Scholar
• ThébaudBInhaled and exhaled nitric oxideCell Mol Life Sci1999558911031112
   Web of Science ®Google Scholar
• LowsonSMAlternatives to nitric oxideBr Med Bull20047011913115531733
   PubMed Web of Science ®Google Scholar
• OrtitzRMExtracorporeal membrane oxygenation in pediatric respiratory failurePediatr Clin North Am198734139463808772
   PubMed Web of Science ®Google Scholar
• The Neonatal Inhaled Nitric Oxide Study GroupInhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failureNew Eng J Med19973365976049036320
   PubMed Web of Science ®Google Scholar
• KinsellaJPInhaled nitric oxide therapy in childrenPaediatr Respir Rev20056319019816153568
   PubMedGoogle Scholar
• AbmanSHNeonatal pulmonary hypertension: a physiologic approach to treatmentPediatr Pulmonol Suppl20042612712815029626
   PubMedGoogle Scholar
• LevinDLPersistent pulmonary hypertension of the newborn infantJ Pediatr1976894626630784932
   PubMed Web of Science ®Google Scholar
• HermonMIntravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control studyArtif Organs1999231197597810564300
   PubMed Web of Science ®Google Scholar
• GöthbergSResidual pulmonary hypertension in children after treatment with inhaled nitric oxide: a follow-up study regarding cardiopulmonary and neurological symptomsActa Paediatr200089121414141911195228
   PubMed Web of Science ®Google Scholar
• BizzarroMInhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart diseaseCochrane Database Syst Rev20094CD005055
   Google Scholar
• MacraeDJInhaled nitric oxide therapy in neonates and children: reaching a European consensusIntensive Care Med200430337238014722629
   PubMed Web of Science ®Google Scholar
• ChouPPulmonary changes following extracorporeal membrane oxygenation: autopsy study of 23 casesHum Pathol19932444054128491481
   PubMed Web of Science ®Google Scholar
• ClarkRHLow-dose nitric oxide therapy for persistent pulmonary hypertension: 1 year follow-upJ Perinatol200323430030312774137
   PubMedGoogle Scholar
• FakiogluHHypoxic respiratory failure in term newborns: clinical indicators for inhaled nitric oxide and extracorporeal membrane oxygenation therapyJ Crit Care200520328829316253800
   PubMed Web of Science ®Google Scholar
• LammersAEEpoprostenol treatment in children with severe pulmonary hypertensionHeart2007673974317065181
   PubMed Web of Science ®Google Scholar
• MaiyaSResponse to bosentan in children with pulmonary hypertensionHeart200692566467016216850
   PubMed Web of Science ®Google Scholar
• WimmerMExperience with long-term nifedipine therapy in paediatric cardiological patientsPadiatr Padol19902531811932116616
   PubMedGoogle Scholar
• HoudeCProfile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilatorsBr Heart J19937054614688260279
   PubMedGoogle Scholar
• MawatariEAmlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure loweringClin Exp Pharmacol Physiol200734759460017581214
   PubMed Web of Science ®Google Scholar
• AdatiaIInhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantationJ Am Coll Cardiol1995257165616647759720
   PubMed Web of Science ®Google Scholar
• WeimannJSildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertensionAnesthesiology20009261702171210839922
   PubMed Web of Science ®Google Scholar
• ReffelmannTTherapeutic potential of phosphodiesterase 5 inhibition for cardiovascular diseaseCirculation2003108223924412860892
   PubMed Web of Science ®Google Scholar
• LeibovitchLTherapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertensionDrugs2007671577317209664
   PubMed Web of Science ®Google Scholar
• HumplTBeneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot studyCirculation2005111243274328015956137
   PubMed Web of Science ®Google Scholar
• RossiRSildenafil improves endothelial function in patients with pulmonary hypertensionPulm Pharmacol Ther200821117217717428713
   PubMed Web of Science ®Google Scholar
• DillerGPCirculating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertensionCirculation2008117233020303018519847
   PubMed Web of Science ®Google Scholar
• BarnettCFSildenafil in the treatment of pulmonary hypertensionVasc Health Risk Manag20062441142217323595
   PubMedGoogle Scholar
• SpringRMSildenafil for pulmonary hypertension: dose-dependent improvement in exercise performancePulm Pharmacol Ther200821351652118249145
   PubMed Web of Science ®Google Scholar
• GalièNSildenafil citrate therapy for pulmonary arterial hypertensionN Engl J Med20053532148215716291984
   PubMed Web of Science ®Google Scholar
• BharaniAThe efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertensionIndian Heart J200355555912760589
   PubMedGoogle Scholar
• AtzAMSildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crisesJ Thorac Cardiovasc Surg2002124362862912202882
   PubMed Web of Science ®Google Scholar
• KothariSSChronic oral sildenafil therapy in severe pulmonary artery hypertensionIndian Heart J200254440440912462669
   PubMedGoogle Scholar
• LeeSHCurrent treatment strategies for pulmonary arterial hypertensionJ Intern Med2005258319921516115293
   PubMed Web of Science ®Google Scholar
• Della TorreFSildenafil in pulmonary hypertensionSarcoidosis Vasc Diffuse Lung Dis2005221787915881285
   PubMed Web of Science ®Google Scholar
• TeixeiraCEDifferential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aortaJ Pharmacol Exp Ther2006316265466116204472
   PubMed Web of Science ®Google Scholar
• ToqueHAVardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed plateletsBr J Pharmacol2008154478779618536732
   PubMed Web of Science ®Google Scholar
• LangIMPaediatric pulmonary vascular diseasePaediatr Respir Rev20045323824815276136
   PubMedGoogle Scholar
• GiaidAExpression of endothelin-1 in the lungs of patients with pulmonary hypertensionN Engl J Med199332824173217398497283
   PubMed Web of Science ®Google Scholar
• CacoubPEndothelin-1 in pulmonary hypertensionN Engl J Med199332926196719688247067
   PubMed Web of Science ®Google Scholar
• RosenzweigEBEffects of long-term bosentan in children with pulmonary arterial hypertensionJ Am Coll Cardiol200546469770416098438
   PubMed Web of Science ®Google Scholar
• GalièNBosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled studyCirculation20061141485416801459
   PubMed Web of Science ®Google Scholar
• GiannakoulasGBosentan in mild pulmonary hypertensionLancet2008372965117301731author reply 1731.
   PubMedGoogle Scholar
• BeghettiMSafety experience with bosentan in 146 children 2–11years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance programPediatr Res200864220020418414142
   PubMed Web of Science ®Google Scholar
• Van LoonRLELong-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?Am Heart J200715477678217893008
   PubMed Web of Science ®Google Scholar
• ApostolopoulouSCSitaxsentan in pulmonary arterial hypertensionChest200312351772; author reply 1772–177312740304
   PubMedGoogle Scholar
• BarstRJClinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot studyChest200212161860186812065350
   PubMed Web of Science ®Google Scholar
• BenzaRLSitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survivalChest2008134477578218625676
   PubMed Web of Science ®Google Scholar
• MehtaPKEndothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defectsTex Heart Inst J200835325626118941642
   PubMed Web of Science ®Google Scholar
• GalièNAmbrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Circulation2008117233010301918506008
   PubMed Web of Science ®Google Scholar
• TudorAObservations on peripheral microcirculation in young hypertensive patientsRom J Intern Med200543127378
   Google Scholar
• BarstRJVasodilator therapy for primary pulmonary hypertension in childrenCirculation19999991197120810069788
   PubMed Web of Science ®Google Scholar
• RosenzweigEBLong-term prostacyclin for pulmonary hypertension with associated congenital heart defectsCirculation199999141858186510199883
   PubMed Web of Science ®Google Scholar
• RosenzweigEBPulmonary arterial hypertension in childrenPediatr Pulmonol200438122215170869
   PubMed Web of Science ®Google Scholar
• TakaokaSCurrent therapies for pulmonary arterial hypertensionSemin Cardiothorac Vasc Anesth20071113714817536117
   PubMedGoogle Scholar
• BarstRJDiagnosis and treatment of pulmonary artery hypertensionCurr Opin Pediatr1996855125198946133
   PubMedGoogle Scholar
• BadeschDBProstanoid therapy for pulmonary arterial hypertensionJ Am Coll Cardiol20044312 Suppl S56S61S15194179
   PubMed Web of Science ®Google Scholar
• SimonneauGContinuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trialAm J Respir Crit Care Med2002165680080411897647
   PubMed Web of Science ®Google Scholar
• IvyDDTransition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinilAm J Cardiol200799569669817317374
   PubMed Web of Science ®Google Scholar
• VizzaCDLong term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogueHeart200186666166511711462
   PubMed Web of Science ®Google Scholar
• BarstRJBeraprost therapy for pulmonary arterial hypertensionJ Am Coll Cardiol200341122119212512821234
   PubMed Web of Science ®Google Scholar
• BakerSEInhaled iloprost in pulmonary arterial hypertensionAnn Pharmacother2005397–81265127415976392
   PubMed Web of Science ®Google Scholar
• OlschewskiHInhaled iloprost for severe pulmonary hypertensionN Engl J Med2002347532232912151469
   PubMed Web of Science ®Google Scholar
• GesslerTInhaled prostanoids in the therapy of pulmonary hypertensionJ Aerosol Med Pulm Drug Deliv200821111218518827
   PubMed Web of Science ®Google Scholar
• IshikuraKBeneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertensionCirc J200670217417816434811
   PubMed Web of Science ®Google Scholar
• AlapatiVRMechanisms of U46619- and 5-HT-induced contraction of bovine pulmonary arteries: role of chloride ionsBr J Pharmacol200715181224123417592513
   PubMed Web of Science ®Google Scholar
• SomlyoAPSignal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin IIJ Physiol2000522Pt 2:17718510639096
   PubMed Web of Science ®Google Scholar
• ShimokawaHRho-kinase is an important therapeutic target in cardiovascular medicineArterioscler Thromb Vasc Biol20052591767177516002741
   PubMed Web of Science ®Google Scholar
• AbeKLong-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in ratsCirc Res200494338539314670839
   PubMed Web of Science ®Google Scholar
• FukumotoYRecent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitorsTohoku J Exp Med2007211430932017409670
   PubMed Web of Science ®Google Scholar
• FukumotoYAcute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertensionHeart200591339139215710736
   PubMed Web of Science ®Google Scholar
• JanosiTDifferential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lungExp Physiol200893111210121918567602
   PubMed Web of Science ®Google Scholar
• TofovicSP2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodelingVascul Pharmacol20084846174183
   Web of Science ®Google Scholar
• GurbanovEThe key role of apoptosis in the pathogenesis and treatment of pulmonary hypertensionEur J Cardiothorac Surg200630349950716870458
   PubMed Web of Science ®Google Scholar
• MichelakisEDEmerging concepts and translational priorities in pulmonary arterial hypertensionCirculation20081181486149518824655
   PubMed Web of Science ®Google Scholar
• AltieriDCSurvivin and apoptosis controlAdv Cancer Res200388315212665052
   PubMed Web of Science ®Google Scholar
• GuerardPThe HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOSNaunyn Schmiedebergs Arch Pharmacol2006373640141416896805
   PubMed Web of Science ®Google Scholar
• RakotoniainaZCelecoxib but not the combination of celecoxib +atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the ratNaunyn Schmiedebergs Arch Pharmacol2008378324125118542928
   PubMed Web of Science ®Google Scholar
• McMurtryMSStatin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin studyAm J Physiol Lung Cell Mol Physiol20072934L933L94017675370
   PubMed Web of Science ®Google Scholar
• HervéPIncreased plasma serotonin in primary pulmonary hypertensionAm J Med19959932492547653484
   PubMed Web of Science ®Google Scholar
• MacLeanMROverexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertensionCirculation2004109172150215515078799
   PubMed Web of Science ®Google Scholar
• MarcosESerotonin transporter inhibitors protect against hypoxic pulmonary hypertensionAm J Respir Crit Care Med2003168448749312773327
   PubMed Web of Science ®Google Scholar
• GuignabertCSerotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in ratsCirculation2005111212812281915927991
   PubMed Web of Science ®Google Scholar
• KawutSMSelective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertensionPulm Pharmacol Ther200619537037416483811
   PubMed Web of Science ®Google Scholar
• ArimaMClinical features of acute pulmonary thromboembolism in younger patientsCirc J200367433033312655164
   PubMed Web of Science ®Google Scholar
• CastilloLWhole body nitric oxide synthesis in healthy men determined from [15N] arginine-to-[15N] citrulline labelingProc Natl Acad Sci U S A19969311460114658876157
   PubMed Web of Science ®Google Scholar
• McMullanDMAlterations in endogenous nitric oxide production after cardiopulmonary bypass in lambs with normal and increased pulmonary blood flowCirculation2000102supplIII172III17811082382
   PubMedGoogle Scholar
• BarrFEEffect of cardiopulmonary bypass on urea cycle intermediates and nitric oxide levels after congenital heart surgeryJ Pediatr2003142263012520250
   PubMed Web of Science ®Google Scholar
• GorenfloMPlasma L-arginine and metabolites of nitric oxide synthase in patients with left-to-right shunt after intracardiac repairChest200512741184118915821193
   PubMed Web of Science ®Google Scholar
• TanakaEPulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatmentJ Rheumatol200229228228711838845
   PubMed Web of Science ®Google Scholar
• HoeperMMDrug treatment of pulmonary arterial hypertension: current and future agentsDrugs200565101337135415977967
   PubMed Web of Science ®Google Scholar
• FasnachtMSSwiss Society for Pulmonary Arterial HypertensionThe Swiss registry for pulmonary arterial hypertension: the paediatric experienceSwiss Med Wkly20071373536510513
   Web of Science ®Google Scholar
• MogollónMVCombination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case reportTransplant Proc20063882522252317097987
   PubMed Web of Science ®Google Scholar
• LiuCEndothelin receptor antagonists for pulmonary arterial hypertensionCochrane Database Syst Rev20063CD00443416856046
   PubMedGoogle Scholar
• DriscollJAMedical therapy for pulmonary arterial hypertensionExpert Opin Pharmacother200891658118076339
   PubMed Web of Science ®Google Scholar
• HumbertMTreatment of pulmonary arterial hypertensionN Engl J Med2004351141425143615459304
   PubMed Web of Science ®Google Scholar
• McLaughlinVVRandomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertensionAm J Respir Crit Care Med2006174111257126316946127
   PubMed Web of Science ®Google Scholar
• HaraldssonAInhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic studyJ Cardiothorac Vasc Anesth19961078648688969392
   PubMed Web of Science ®Google Scholar
• BurgessGMutual phar-macokinetic interactions between steady-state bosentan and sildenafilEur J Clin Pharmacol2008641435018040672
   PubMed Web of Science ®Google Scholar
• SimonneauGAddition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trialAnn Intern Med2008149852153018936500
   PubMed Web of Science ®Google Scholar
• KersteinDBlade balloon atrial septostomy in patients with severe primary pulmonary hypertensionCirculation1995917202820357534664
   PubMed Web of Science ®Google Scholar
• RichSAtrial septostomy as palliative therapy for refractory primary pulmonary hypertensionAm J Cardiol1983519156015616189385
   PubMed Web of Science ®Google Scholar
• LawMAAtrial septostomy improves survival in select patients with pulmonary hypertensionAm Heart J2007153577978417452153
   PubMed Web of Science ®Google Scholar
• HausknechtMJSuccessful palliation of primary pulmonary hypertension by atrial septostomyAm J Cardiol19906515104510461691586
   PubMed Web of Science ®Google Scholar
• SandovalJGraded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatmentJ Am Coll Cardiol199822973049708453
   PubMed Web of Science ®Google Scholar
• CheeverKHAn overview of pulmonary arterial hypertension: risks, pathogenesis, clinical manifestations, and managementJ Cardiovasc Nurs2005202108116quiz 117–118.15855858
   PubMedGoogle Scholar
• HuddlestonCBLung transplantation in childrenAnn Surg2002236327027612192313
   PubMed Web of Science ®Google Scholar
• AuroraPRegistry of the International Society for Heart and Lung Transplantation: eleventh official pediatric lung and heart/lung transplantation report – 2008J Heart Lung Transplant200827997898318765189
   PubMedGoogle Scholar
• HaworthSGRole of the endothelium in pulmonary arterial hypertensionVascul Pharmacol200645531732517005453
   PubMed Web of Science ®Google Scholar
• Galie’NTreatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trialLancet20083712093210018572079
   PubMed Web of Science ®Google Scholar
• GalieNA meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEur Heart J20093039440319155250
   PubMed Web of Science ®Google Scholar
• RubinLJTreatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trialAnn Intern Med19901124854912107780
   PubMed Web of Science ®Google Scholar
• BarstRJA comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study GroupN Engl J Med19963342963028532025
   PubMed Web of Science ®Google Scholar
• BadeschDBContinuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialAnn Intern Med200013242543410733441
   PubMed Web of Science ®Google Scholar
• ChannickRNEffects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet20013581119112311597664
   PubMed Web of Science ®Google Scholar
• LanglebenDEffects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertensionAm Heart J2002143E412040360
   PubMed Web of Science ®Google Scholar
• GalieNEffects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trialJ Am Coll Cardiol2002391496150211985913
   PubMed Web of Science ®Google Scholar
• RubinLJBosentan therapy for pulmonary arterial hypertensionN Engl J Med200234689690311907289
   PubMed Web of Science ®Google Scholar
• SastryBKSClinical efficacy of sildenafil in primary pulmonary hypertension. 1: A randomized, placebo-controlled, doubleblind, crossover studyJ Am Coll Cardiol2004431149115315063421
   PubMed Web of Science ®Google Scholar
• HumbertMCombination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2Eur Respir J20042435335915358690
   PubMed Web of Science ®Google Scholar
• BarstRJSitaxsentan therapy for pulmonary arterial hypertensionAm J Respir Crit Care Med2004169444144714630619
   PubMed Web of Science ®Google Scholar
• GalieNThe Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertensionN Engl J Med20053532148215716291984
   PubMed Web of Science ®Google Scholar
• WilkinsMRSildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) studyAm J Respir Crit Care Med20051711292129715750042
   PubMed Web of Science ®Google Scholar
• SinghTA randomized, placebo controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertensionAm Heart J2006151851.e1851.e5
   PubMed Web of Science ®Google Scholar
• BarstRJTreatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentanJ Am Coll Cardiol200647102049205616697324
   PubMed Web of Science ®Google Scholar
• McLaughlinVVRandomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertensionAm J Respir Crit Care Med20061741257126316946127
   PubMed Web of Science ®Google Scholar
• HoeperMCombining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertensionEur Resp J20064691694
   Google Scholar
• HislopADevelopmental biology of the pulmonary circulationPaediatr Respir Rev200561354315698814
   PubMedGoogle Scholar
• TorresFSystematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertensionInt J Clin Pract200761101756176517877662
   PubMed Web of Science ®Google Scholar